CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program
30 mars 2022 17h00 HE
|
CytoDyn Inc.
Live webcast to be held March 31 discussing announcement VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage...
CytoDyn to Hold Webcast to Provide Company Update
30 mars 2022 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn to Hold Webcast and Live Q/A on January 13
11 janv. 2022 16h35 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn to Hold Webcast and Live Q/A on December 14
10 déc. 2021 15h59 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Dec. 10, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn Reminds Stockholders to Register 24 hours before November 24th Annual Meeting
16 nov. 2021 14h00 HE
|
CytoDyn Inc.
Management Team Will Present on Company’s Strategy Going Forward VANCOUVER, Washington, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage...
CytoDyn Submits the First of Three Main Sections of HIV BLA to FDA Under Previously Authorized Rolling Review
16 nov. 2021 06h00 HE
|
CytoDyn Inc.
Second portion out of three major portions of BLA (CMC portion) will be submitted shortly Clinical section (last portion to complete BLA) expected to be submitted during Q1 2022 VANCOUVER,...
CytoDyn Submits Breakthrough Therapy Designation Application to FDA for Leronlimab as a Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC); Fast Track Designation for mTNBC was received previously
08 nov. 2021 06h00 HE
|
CytoDyn Inc.
Ongoing analysis of data from 28 mTNBC patients following 12 months of treatment with leronlimab is very encouraging given little-to-no effective treatment options currently VANCOUVER,...
CytoDyn Reports Preliminary Results from First Five Patients in Phase 2 NASH Open Label Leronlimab Trial. Lower Fatty Deposits in All 5 Patients by as Much as 45% and Lower Fibrosis in 4 Patients by as Much as 10% Compared to Baseline.
03 nov. 2021 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Nov. 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn Announces Cancer Update: 12-month Analysis of 28 mTNBC Patients Receiving Leronlimab Suggests an Increase of 3600% in 12-month OS in 75% of Patients with a Lower Level of Circulating Cells After Leronlimab Induction or at Baseline; 12-month PFS Continues at Near 600% Increase
03 nov. 2021 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Nov. 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA
28 oct. 2021 00h41 HE
|
CytoDyn Inc.
Management expects the non-clinical and CMC sections of the BLA to be resubmitted to FDA in November VANCOUVER, Washington, Oct. 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn"...